A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Mirabegron (Primary)
- Indications Neurogenic bladder
- Focus Therapeutic Use
- 09 Feb 2018 Status changed from recruiting to discontinued due to slow recruitment and small observed effect size.
- 21 Mar 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 21 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.